An Open-label Randomized Study to Evaluate the Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) in Treatment-naïve Patients With Newly Diagnosed Drug-sensitive Sputum Smear-positive Pulmonary Tuberculosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Telacebec (Primary) ; Rifampicin/isoniazid/pyrazinamide/ethambutol
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors Qurient Co
- 10 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.
- 28 Jun 2018 New trial record